Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Polaryx Therapeutics, Inc. (PLYX)

Polaryx Therapeutics names Will Charlton, M.D., as Chief Medical Officer, effective Sept. 1

Neutral Impact 3 of 5 leadership Written later

Polaryx Therapeutics appointed Will Charlton, M.D., M.A.S., as its Chief Medical Officer, effective September 1, 2026, ahead of the planned SOTERIA Phase 2 trial start in the fourth quarter of 2026. The filing describes his prior roles as Chief Medical Officer at Spruce Biosciences and senior clinical development executive at Tyra Biosciences, and the company says his experience supports its clinical leadership. The filing contains no financial results or guidance, so the appointment is a leadership change rather than a change in reported performance.

Key points

  • Will Charlton, M.D., M.A.S., appointed Chief Medical Officer effective September 1, 2026; appointment announced August 27, 2026 and disclosed in a press release dated September 1, 2026
  • Previously Senior Vice President, Clinical Development, Skeletal Dysplasia at Tyra Biosciences (March 2025 to June 2026) and Chief Medical Officer at Spruce Biosciences (March 2022 to January 2025)
  • Company plans to initiate the SOTERIA Phase 2 trial of lead candidate PLX-200 in the fourth quarter of 2026; the company received an FDA safe to proceed letter in October 2025

The filing

CompanyPolaryx Therapeutics, Inc. (PLYX)
Form8-K, current report
Filed with the SECSep 1, 2026, 4:30 PM ET
Accession number0001213900-26-096235

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.